Rich Pharmaceuticals Announces Letter Of Intent With Faculty Of Medicine At Khon Kaen University To Conduct Acute Myelocytic Leukemia Clinical Trials

BEVERLY HILLS, Calif., March 24, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich Pharmaceuticals" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML) and Hodgkin's Lymphoma, announced that it has entered into a Letter of Intent with The Faculty of Medicine at Khon Kaen University, Thailand to conduct clinical trials using Rich's lead molecule, RP-323 in treating AML patients.

The Faculty of Medicine at Khon Kaen University has established itself as a center for world-class research. Presently, the Faculty has four Research Centers of Excellence and 23 Research Groups doing clinical research across numerous disease states with emphasis in conducting oncology clinical trials. For more information on the Faculty of Medicine, Khon Kaen University see: http://www.md.kku.ac.th/en/. The commencement of the clinical studies is conditioned upon establishing a budget and timeline for the studies, and the execution of a definitive Clinical Study Agreement with the Faculty of Medicine at Khon Kaen University. The clinical studies are estimated to include 36 patients and 3 separate sites.

"As we move closer to beginning our AML clinical program, we are continuing to work diligently in securing additional principal investigators in the United States and finalizing our IND submission to the FDA," said Ben Chang, CEO of Rich Pharmaceuticals.

Rich Pharmaceuticals'RP-323 is a phorbol ester, which induces differentiation and/or apoptosis in multiple cell lines and primary cells, activates protein kinase C (PKC), and modulates the activity of multiple downstream cell signaling pathways, including mitogen-activated protein kinase (MAPK) pathways. TPA induces PKC to produce NF kappa, which produces NF kappa B that has the ability to regulate cellular responses by entering into the nucleus of cell. NF kappa B binds to DNA and changes the nature of the cell and (1) induces differentiation; (2) induces proliferation; (3) cytokine induction; (4) and/or apoptosis.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia, is the most common acute leukemia type that affects adults. AML is an aggressive form of cancer of the blood and the bone marrow, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal white blood cells. In the U.S., about 18,000 new cases of AML are diagnosed annually.

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. (OTCQB: RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at www.richpharmaceuticals.com.

For more infomraiton about AML see for example:

http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page1 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/

For more information about Hodgkin's Lymphoma see for example:

http://www.cancer.gov/cancertopics/types/hodgkin 
http://www.cancer.org/cancer/hodgkindisease/

Notice Regarding Forward-Looking Statements:

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to raise the additional funding we need to continue to pursue our business and product development plans and to conduct our planned clinical studies; our ability to develop and commercialize products based on our technology platform; competition in the industry in which we operate; and general market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

Contact:

Ben Chang, CEO
9595 Wilshire Blvd., Suite 900
Beverly Hills, CA 90212
424-230-7001 EXT 105

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-inc-announces-letter-of-intent-with-faculty-of-medicine-at-khon-kaen-university-to-conduct-acute-myelocytic-leukemia-clinical-trials-300055020.html

SOURCE Rich Pharmaceuticals, Inc.